Why Is HIMS & HERS HEALTH I A (HIMS) Stock Down Today?

HIMS stock is down 14.20% at $28.09 as of the latest trading update. The decline follows a recent surge driven by positive FDA advisory panel news on peptides, which appears to have reversed as traders reassess the outlook. The stock opened with a modest gap up but has since fallen into negative territory, reflecting shifting sentiment in the market.

What Happened

An FDA advisory panel had previously backed six of seven peptides for potential inclusion on the 503A compounding list, sparking optimism among investors. This led to a sharp overnight rise in HIMS stock as retail traders anticipated regulatory progress. However, the market has since turned bearish, with the stock reversing its gains and falling sharply in the early morning session. The lone rejection of Emideltide and broader skepticism about the commercial viability of peptides may have contributed to the reversal. Additionally, Martin Shkreli, a prominent figure in the biotech space, has publicly criticized the peptides as "fake medicine," further fueling doubts.

What The Data Shows

Over the last eight sessions, HIMS has fallen 24.4%, from $37.17 to $28.09. The stock opened at $28.60 on Friday but has since declined to $28.66, with a session high of $28.85 and a low of $28.54. Volume remains subdued at 0.2 million shares, far below the 3-month daily average. Insider activity has also been bearish, with the CFO, Okupe Oluyemi, selling shares on three occasions in the past month. Retail chatter on platforms like Reddit has remained sparse, with only one post in the last seven days.

What To Watch

Traders should monitor coverage breadth as the market digests the FDA advisory panel outcome. No earnings date is currently scheduled, but analyst activity remains active, with Truist and Citigroup recently adjusting their price targets.